创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

袁漪, 何华, 柳晓泉. 抗肿瘤药物心脏安全性评价的药动学-药效学模型[J]. 药学进展, 2019, 43(7): 535-543.
引用本文: 袁漪, 何华, 柳晓泉. 抗肿瘤药物心脏安全性评价的药动学-药效学模型[J]. 药学进展, 2019, 43(7): 535-543.
YUAN Yi, HE Hua, LIU Xiaoquan. Pharmacokinetic-Pharmacodynamic Model for Cardiac Safety Assessment of Antitumor Drugs[J]. Progress in Pharmaceutical Sciences, 2019, 43(7): 535-543.
Citation: YUAN Yi, HE Hua, LIU Xiaoquan. Pharmacokinetic-Pharmacodynamic Model for Cardiac Safety Assessment of Antitumor Drugs[J]. Progress in Pharmaceutical Sciences, 2019, 43(7): 535-543.

抗肿瘤药物心脏安全性评价的药动学-药效学模型

Pharmacokinetic-Pharmacodynamic Model for Cardiac Safety Assessment of Antitumor Drugs

  • 摘要: 抗肿瘤治疗导致的心血管毒性已成为癌症幸存者继肿瘤复发后的第二大病发和死亡原因。在抗肿瘤治疗中控制心血管不良反应的发生成为肿瘤治疗的一大难题。药动学-药效学(PK-PD)结合模型通过数学模型的方法建立药物剂量与药物效应之间的定量关系,可用于预测药物的药效或毒性,是研究药物与机体相互作用的重要工具。建立心血管毒性PK-PD模型能够预测抗肿瘤药物心血管毒性,为高效低毒的肿瘤治疗策略制定提供重要的参考依据。

     

    Abstract: Anti-tumor therapy-related cardiotoxicity is the second leading cause of morbidity and mortality among cancer survivors after recurrent malignancy. The prevention of cardiovascular complications has become a great challenge in anti-tumor therapy. The pharmacokinetic-pharmacodynamic (PK-PD) model is a mathematical model-based approach to establishing the drug exposure-response relationship. The application of PK-PD model is highly beneficial for predicting cardiotoxicity of anti-tumor agents, so as to provide reference for cancer treatment strategies with high efficiency and low toxicity.

     

/

返回文章
返回